MedTrace Logo

Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer

NCT07730138 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 384

Last updated 2026-07-28

No results posted yet for this study

Summary

A Multinational, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group, Phase 3 Study to Evaluate the Efficacy and Safety of DWP14012 in Participants with Gastric Ulcer

Conditions

  • Gastric Ulcer

Interventions

DRUG

DWP14012 40mg (Fexuprazan)

DWP14012 40mg(Fexuprazan) + placebo of Lansoprazole

DRUG

Lansoprazole 30mg

Lansoprazole 30mg + Placebo of DWP14012 40mg

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-15
Primary Completion
2028-04-15
Completion
2028-10-15

Countries

  • Indonesia
  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07730138 on ClinicalTrials.gov